HC Wainwright reissued their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY - Free Report) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $75.00 price target on the stock.
A number of other analysts have also recently issued reports on the company. Raymond James reissued an "outperform" rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Cantor Fitzgerald increased their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Needham & Company LLC reiterated a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday. Mizuho increased their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Finally, Oppenheimer restated an "outperform" rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and a consensus price target of $55.00.
View Our Latest Stock Report on Harmony Biosciences
Harmony Biosciences Price Performance
Shares of NASDAQ HRMY traded up $0.51 during mid-day trading on Thursday, reaching $39.05. The company had a trading volume of 658,904 shares, compared to its average volume of 533,591. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 1-year low of $28.14 and a 1-year high of $41.61. The stock has a market cap of $2.23 billion, a PE ratio of 18.51, a P/E/G ratio of 0.49 and a beta of 0.78. The company has a 50-day moving average price of $34.34 and a two-hundred day moving average price of $34.78.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million during the quarter, compared to analysts' expectations of $184.07 million. During the same period last year, the company posted $0.63 earnings per share. The business's revenue for the quarter was up 16.0% on a year-over-year basis. On average, equities analysts anticipate that Harmony Biosciences will post 2.42 earnings per share for the current year.
Insider Buying and Selling at Harmony Biosciences
In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 30.80% of the company's stock.
Institutional Trading of Harmony Biosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock valued at $80,000 after purchasing an additional 360 shares during the period. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after acquiring an additional 436 shares during the period. Profund Advisors LLC raised its stake in Harmony Biosciences by 11.1% during the second quarter. Profund Advisors LLC now owns 7,557 shares of the company's stock worth $228,000 after acquiring an additional 758 shares in the last quarter. CWM LLC lifted its holdings in shares of Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after acquiring an additional 775 shares during the period. Finally, Mendota Financial Group LLC boosted its stake in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. Institutional investors own 86.23% of the company's stock.
About Harmony Biosciences
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
